Erasca, Inc. ERAS
Regular-session close
After hours · Nov 20, 4:51 PM ET
- YTD
- +265.86%
- 1 year
- +389.57%
5D -2.16 (-13.70%)
- Market cap
- 4.78B
- EPS (ttm)
- -0.97
- Shares out
- 350.96M
- Forward P/E
- -17.36
- YTD return
- +265.86%
- 1-year return
- +389.57%
- 50-day average
- 14.81
- 200-day average
- 15.33
- Enterprise value
- 4.39B
- Price / book
- 5.20
- Volume
- 11.07M
- Avg volume
- 5.14M
- Open
- 13.13
- Previous close
- 14.22
- Day's range
- 13.13 – 14.30
- 52-week range
- 2.75 – 24.28
- Beta
- 0.65
- Analysts
- Buy
- Price target
- 25.10 (+84.4%)
- Earnings date
- Mar 11, 2027
Key statistics
- Free cash flow
- -207.85M
- Total cash
- 643.70M
- Total debt
- 43.41M
- Return on equity
- -48.70%
- Short % of float
- 11.74%
Fundamental scorecard
3 of 25 checks passed on ERAS’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 20.00
- Target (mean)
- 25.10
- Target (high)
- 35.00
- Strong buy2
- Buy6
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -0.15777.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Dec 30, 2026 | -0.15 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.13013 | -0.15 | -0.02 | -15.27% |
| Aug 12, 2026 | Jun 30, 2026 | -0.11137 | -0.14 | -0.03 | -25.71% |
| May 11, 2026 | Mar 31, 2026 | -0.11152 | -0.60 | -0.49 | -438.02% |
| Mar 12, 2026 | Dec 31, 2025 | -0.11 | -0.10 | +0.01 | +9.09% |
| Nov 12, 2025 | Sep 30, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | main | Neutral | Neutral |
| Aug 13, 2026 | Guggenheim | main | Buy | Buy |
| Aug 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 20, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Jul 14, 2026 | B of A Securities | main | Neutral | Neutral |
| Jun 4, 2026 | B of A Securities | up | Underperform | Neutral |
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015; and clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 in clinical study with Navlimetostat. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- erasca.com
News
Erasca, Inc. (ERAS) Discusses Phase I Efficacy and Safety Data for Pan-RAS Molecular Glue ERAS-0015 Transcript
Erasca Throws Down A Gauntlet — And Revolution Throws It Right Back
Erasca: 'Buy' On Expanded KRAS Targeting ERAS-4001 And Bristol-Myers Squibb Collaboration Tie-Up
Erasca Accelerates Pancreatic Cancer Study After Encouraging Monotherapy, Combination Results
Erasca's pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on ERAS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARNER EBUN S | Officer | Conversion of Exercise of derivative security | Mar 31, 2026 | 25,076 |
| MORRIS SHANNON R. M.D., PH.D. | Officer | Conversion of Exercise of derivative security | Mar 3, 2026 | 0 |
| MULTANI PRATIK S | Director | Stock Gift | May 22, 2025 | 172,866 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8.40% | 29,475,188 | 401.16M | Sep 29, 2026 |
| Blackrock Inc. | 6.76% | 23,736,078 | 323.05M | Sep 29, 2026 |
| RTW Investments LP | 6.40% | 22,446,754 | 305.50M | Sep 29, 2026 |
| Venrock Adviser, LLC | 5.72% | 20,089,932 | 273.42M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 4.90% | 17,192,148 | 233.99M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.96% | 13,905,796 | 189.26M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.39% | 8,384,454 | 114.11M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.39% | 8,381,324 | 114.07M | Sep 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.98% | 6,954,600 | 94.65M | Jun 29, 2026 |
| SmallCap World Fund Inc | 1.96% | 6,886,446 | 93.72M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.63% | 5,734,875 | 78.05M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.95% | 3,334,921 | 45.39M | Jun 29, 2026 |
